MSH|^~\&|PDMS|MDACC|CTMS|NCI|||CSU^C09 <cr>
CMO|1|T93-0800^^NCI|ID93-030^Ph I Study of Oral Fostriecin^MDACC|
|235^Alexander^Susan^B.^^^MD^MDACC|19940801|14|19941205|^Sam Smith <cr>
CM2|1|^Prestudy^NCI|Prestudy Eligibility and Baseline Clinical Params|
^CBC~^SMA12~^Pathology~^Elig.checklist~^Prestudy Form~^
Imaging procedures as indicated <cr>
CM2|2|^Course Completion^NCI|Course Completion Toxicity and Response .....Evaluation|Adverse Events Form~^Course Completion Form~^CEA <cr>
PID|1|235925||J^F^M||19350616 <cr> |
[note: anonymous] |
CSR||T93-080^^NCI|ID93-030^^MDACC|MDACC|14||19941205 <cr>
CSS||^Prestudy|19941204|C^compliant^NCI <cr>
OBR|1|||3^EligibilChecklist^StudyFormsList|||19941205 <cr>
OBX|1|CE|ELIG1^Elig Crit 1^NCI|Text Elig Crit 1|Y <cr>
OBX|2|CE|ELIG2^Elig Crit 2^NCI||Y <cr>
OBR|2|||4^Prestudy Form^StudyFormsList|||19941205 <cr>
OBX|1|CE|QOL^Quality of Life^NCI||2&3&2&4&2^SPITZER <cr>
OBX|2|CE|PRICHEM^Prior Chemo^NCI||Yes <cr>
OBX|3|CE|PRIBIOL^Prior Biologics^NCI||No <cr>
OBX|4|NM|NUMREM^Number Prior Remissions^NCI||2 <cr>
OBR|3|||88304^SURG PATH REPORT|||19940101 <cr>
OBX|1|CE|88304&ANT|1|9999^PANCREAS^SNM <cr>
OBX|2|CE|88304&IMP|2|9999^ADENOCARCINOMA^SNM <cr>
OBR|4|||85022^CBC|||199412050800 <cr>
OBX|1|ST|718-7^HEMOGLOBIN:^LN||13.4|GM/DL|14-18|N||S|F|19860522<cr>
[cbc values]
OBX|2|ST|4544-3^HEMATOCRIT:^LN||40.3|%|42-52|L||S|F|19860522 <cr>
OBX|3|ST|789-8^ERYTHROCYTES:^LN||4.56|10*6/ml|4.7-6.1|L||S|F|19860522 <cr>
OBX|4|ST|787-22^ERYTHROCYTE MEAN CORPUSCULAR VOLUME:^LN||88|fl
|80-94|N||S|F|19860522 <cr>
OBX|5|ST|785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN:^LN||29.5|pg
|27-31|N||N|F|19860522 <cr>
OBX|6|ST|786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION:^LN|
|33|%|33-37|N||N|F|19860522 <cr>
OBX|7|ST|6690-2^LEUKOCYTES:^LN||10.7|10*3/ml|4.8-10.8|N||N|F|19860522 <cr>
OBX|8|ST|764-1^NEUTROPHILS BAND FORM/100 LEUKOCYTES:^LN||2|%||||F <cr>
OBX|9|ST|769-0^NEUTROPHILS SEGMENTED/100 LEUKOCYTES:^LN||67|%||||F <cr>
OBX|10|ST|736-9^LYMPHOCYTES/100 LEUKOCYTES:^LN||29|%||||F <cr>
OBX|11|ST|5905-5^MONOCYTES/100 LEUKOCYTES:^LN||1|%||||F <cr>
OBX|12|ST|713-8^EOSINOPHILS/100 LEUKOCYTES:^LN||2|%||||F <cr>
OBR|5|||80004^ELECTROLYTES|||199412050800 <cr>
OBX|1|ST|2947-0^SODIUM:^LN||150|mmol/l|136-148|H||A|F|19850301 <cr>
OBX|2|ST|2823-3^POTASSIUM:^LN||4.5|mmol/l|3.5-5|N||N|F|19850301 <cr>
[electrolytes values]
OBX|3|ST|2069-3^CHLORIDE:^LN||102|mmol/l|94-105|N||N|F|19850301 <cr>
OBX|4|ST|2028-9^CARBON DIOXIDE.TOTAL:^LN||27|mmol/l|24-31|N||N|F
|19850301<cr>
CSP|1|^Course 1|19941205|19950120|Y^Toxicity and Response^NCI <cr>
CSS|1|^Course Completion|19950120| <cr>
OBR|1|||2039-6^CARCINOEMBRYONIC AG:^LN|||19941008 <cr>
OBX|1|NM|2039-6^CARCINOEMBRYONIC AG:^LN||15.2|IU <cr>
OBR|2|||10^Course Completion Form^StudyPhaseFormsList|||19950120 <cr>
OBX|1|CE|CRSRESP^Course Response^NCI||4^Partial Response <cr>
OBX|2|NM|DRUGDISP^Capsules Dispensed^NCI||60 <cr>
OBX|3|NM|DRUGRETN^Capsules Returned^NCI||5 <cr>
OBX|4|ID|DXCOMP^Diagnostic Tests Compliance^NCI||Y <cr>
OBX|5|CE|PERSTAT^Performance Status^NCI||3^ZUBRODS <cr>
OBR|3|||9999^Adverse Events <cr> OBX|1|CE|9999&EVENT|1|45^Vomiting^NCI <cr> OBX|2|DT|9999&ONSET|1|19941215 <cr> OBX|3|DT|9999&RESOLUTION|1|19941217 <cr> |
[Note: Needs to maintain compatibility with ongoing product experience message efforts.] |
OBX|4|ID|9999&GRADE|1|M^MODERATE <cr> OBX|5|ID|9999&RELATION_TO_RX|1|L^LIKELY <cr> OBX|6|CE|9999&EVENT|2|303^Dyspnea^NCI <cr> OBX|7|DT|9999&ONSET|2|19941231 <cr> OBX|8|DT|9999&RESOLUTION|2 <cr> OBX|9|ID|9999&GRADE|2|MI^MILD <cr> OBX|10|ID|9999&RELATION_TO_RX|2|U^UNLIKELY <cr> |
[Note2: There are other possible OBX suffixes defined by FDA: APEX/ NADIR, ACTION, THERAPY, OUTCOME, RECHALLENGE.] |